Brian Koffman’s Post

In this roundtable discussion at the 65th American Society of Hematology Annual Meeting & Exposition, Drs. Hana Safah, Jamile Shammo, Andrew Brunner, and Tiffany Tanaka share their outlook for the future of myelodysplastic syndromes research and treatments. Watch here: https://buff.ly/4aV7vB8

"Review about the book". Here's what Dr Ify Osunkwo, a hematology and sickle cell disease specialist had to say about our book. Have you ordered yours yet? Order your copy today: https://lnkd.in/erKDDHAJ #sicklcell #sicklecellawareness #book #booklaunch

Do carve out time in your busy schedule to meet Jennell and learn about RBC health biomarkers.

Discover the latest developments in myeloma research from the Annual American Society of Hematology meeting. Clinical trial investigators share their abstract presentations from ASH delving deep into the key research takeaways. Watch Now: https://lnkd.in/gaawhHcq #ASH23

Have you read our recent Q&A with our Reach-the-World Fellow Mark Allan Lim? Learn more about his interest in improving the field of hematology in the Philippines here: https://lnkd.in/eqecTerN

In case you missed the myelodysplastic syndromes roundtable at the 2023 American Society of Hematology Annual Meeting, Drs. Hana Safah, Jamile Shammo, Andrew Brunner, and Tiffany Tanaka cover a study that compared luspatercept and epoetin alfa in myelodysplastic syndromes. Watch the full roundtable: https://buff.ly/3NSI9d8

#Congress | 🔎 What subjects were amplified by #HCPs through social media during #EHA2024? In June, took place the European Hematology Association (EHA) 2024 Hybrid Congress. The following pages provide a brief overview of the volume of conversations, the share of voice of clinical trials most discussed, or top hashtags. Moreover, discover a focus on #multiplemyeloma with the topics of discussions. Access the SML EHA2024 full report by clicking this link 👉 https://lnkd.in/e6-MYzHj

📢All 12 manuscripts in the #SpecialIssue “#Hematologic #Malignancies: Challenges from Diagnosis to Treatment”, led by Dr. Ioanna Sakellari and Dr. Eleni Gavriilaki, Hematology Department and Dr. Eleni Gavriilaki, have been published! 🎉🎉 📌You are welcome to read via the following link: https://lnkd.in/dyADYnGy

Last week I presented the first results of the phase 2 ICON study at the European Hematology Association (EHA) conference in Madrid. In the ICON study, relapsed/refractory multiple myeloma patients were treated with iberdomide, low-dose cyclophosphamide and dexamethasone. Iberdomide is a novel cereblon E3 ligase modulator (CELMoD™) with improved direct anti-myeloma activity and immune-stimulatory effects. This treatment regimen resulted in a ORR of 82% and a median PFS of 17.8 months in patients with 2-4 prior lines of therapy. This fully oral, well tolerated, and active combination warrants further evaluation in RRMM. The full abstract is available online: https://lnkd.in/eUqb4Vaq What an interesting conference the #EHA2024 has been! Thanks to all co-authors and my supervisors Niels Van De Donk, Sonja Zweegman and Tuna Mutis.

NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology